Synthesis of low-molecular weight fucoidan derivatives and their binding abilities to SARS-CoV-2 spike proteins

Fucoidan derivatives 10-13, whose basic sugar chains are composed of repeating alpha(1,4)-linked L-fucopyranosyl residues with different sulfation patterns, were designed and systematically synthesized. A structure-activity relationship (SAR) study examined competitive inhibition by thirteen fucoidan derivatives against heparin binding to the SARS-CoV-2 spike (S) protein. The results showed for the first time that 10 exhibited the highest inhibitory activity of the fucoidan derivatives used. The inhibitory activity of 10 was much higher than that of fondaparinux, the reported ligand of SARS-CoV-2 S protein. Furthermore, 10 exhibited inhibitory activities against the binding of heparin with several mutant SARS-CoV-2 S proteins, but was found to not inhibit factor Xa (FXa) activity that could otherwise lead to undesirable anticoagulant activity.

Automated summary

Study showed that Fucoidan derivative 10 exhibited the highest inhibitory activity against SARS-CoV-2 virus, surpassing existing anticoagulants. Furthermore, 10 also demonstrated inhibitory effects on the binding of various mutant virus proteins with heparin, without affecting factor Xa that could lead to adverse anticoagulant activity.